DE60317098D1 - Carbostyril-derivate mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von gemütskrankheiten - Google Patents

Carbostyril-derivate mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von gemütskrankheiten

Info

Publication number
DE60317098D1
DE60317098D1 DE60317098T DE60317098T DE60317098D1 DE 60317098 D1 DE60317098 D1 DE 60317098D1 DE 60317098 T DE60317098 T DE 60317098T DE 60317098 T DE60317098 T DE 60317098T DE 60317098 D1 DE60317098 D1 DE 60317098D1
Authority
DE
Germany
Prior art keywords
treatment
selective serotonin
mental diseases
carbostyril derivatives
serotonin inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60317098T
Other languages
English (en)
Other versions
DE60317098T2 (de
Inventor
Tetsuro Kikuchi
Taro Iwamoto
Tsuyoshi Hirose
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32716306&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60317098(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE60317098D1 publication Critical patent/DE60317098D1/de
Publication of DE60317098T2 publication Critical patent/DE60317098T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60317098T 2002-12-27 2003-12-25 Carbostyril-derivate mit selektiven serotonin-aufnahmeinhibitoren zur behandlung von gemütskrankheiten Expired - Lifetime DE60317098T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2002379003 2002-12-27
JP2002379003 2002-12-27
US47048103P 2003-05-14 2003-05-14
US470481P 2003-05-14
PCT/JP2003/016724 WO2004060374A1 (en) 2002-12-27 2003-12-25 Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders

Publications (2)

Publication Number Publication Date
DE60317098D1 true DE60317098D1 (de) 2007-12-06
DE60317098T2 DE60317098T2 (de) 2008-08-07

Family

ID=32716306

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60317098T Expired - Lifetime DE60317098T2 (de) 2002-12-27 2003-12-25 Carbostyril-derivate mit selektiven serotonin-aufnahmeinhibitoren zur behandlung von gemütskrankheiten

Country Status (27)

Country Link
US (5) US9387182B2 (de)
EP (2) EP1723957A3 (de)
JP (1) JP4284524B2 (de)
KR (2) KR100842694B1 (de)
CN (2) CN1989968B (de)
AT (1) ATE376419T1 (de)
AU (1) AU2003295235B2 (de)
BR (1) BR0317771A (de)
CA (1) CA2511619C (de)
CY (1) CY1108060T1 (de)
DE (1) DE60317098T2 (de)
DK (1) DK1575590T3 (de)
EC (1) ECSP055885A (de)
ES (1) ES2295677T3 (de)
HK (3) HK1082411A1 (de)
IL (1) IL169358A (de)
MX (1) MXPA05006857A (de)
MY (1) MY152919A (de)
NO (1) NO333291B1 (de)
NZ (2) NZ540054A (de)
PE (1) PE20040923A1 (de)
PL (1) PL211975B1 (de)
PT (1) PT1575590E (de)
RU (2) RU2356554C2 (de)
SI (1) SI1575590T1 (de)
WO (1) WO2004060374A1 (de)
ZA (1) ZA200503873B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2526562C (en) 2003-05-23 2011-06-28 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and mood stabilizers for treating mood disorders
WO2006030446A1 (en) * 2004-09-13 2006-03-23 Matrix Laboratories Ltd Process for the preparation of polymorphs, solvates of aripiprazole using aripiprazole acid salts
AU2005302589B2 (en) 2004-10-28 2010-09-16 Sk Biopharmaceuticals Co., Ltd. Adjunctive therapy for depression
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
AR085840A1 (es) * 2011-04-05 2013-10-30 Otsuka Pharma Co Ltd Medicamento que contiene un compuesto que es 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoxi]-1h-quinolin-2-ona
JO3227B1 (ar) 2011-09-08 2018-03-08 Otsuka Pharma Co Ltd مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
WO2014002553A1 (ja) 2012-06-29 2014-01-03 丸石製薬株式会社 アリピプラゾールの経口医薬製剤
GB2542155B (en) 2015-09-09 2018-08-01 Gw Pharma Ltd Use of cannabidiol in the treatment of mental disorders
CN111455019A (zh) * 2018-05-03 2020-07-28 杭州端丽生物技术有限公司 化合物fty720在制备治疗行为和运动异常检测标记物中的应用
JP7211136B2 (ja) * 2019-02-14 2023-01-24 ニプロ株式会社 錠剤、および、その製造方法
EP3970710A4 (de) 2019-05-13 2023-06-14 VASTHERA Co. Ltd. Pharmazeutische zusammensetzung zur vorbeugung oder behandlung von degenerativen hirnerkrankungen durch autophagieaktivierung
CN114340606A (zh) 2019-05-15 2022-04-12 瓦西特拉有限公司 包含自噬激活剂作为活性成分的用于预防或治疗心脑血管疾病的组合物
US11080484B1 (en) * 2020-10-08 2021-08-03 Omniscient Neurotechnology Pty Limited Natural language processing of electronic records

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4310524A (en) 1980-04-11 1982-01-12 Richardson-Merrell, Inc. TCA Composition and method for rapid onset antidepressant therapy
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP2608788B2 (ja) 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US5591884A (en) 1989-05-31 1997-01-07 Abbott Laboratories Dopamine agonists
US5500343A (en) 1990-02-07 1996-03-19 Board Of Regents, The University Of Texas System Allelic association of the human dopamine(D2) receptor gene in compulsive disorders
US5780051A (en) 1992-04-02 1998-07-14 Dynagen, Inc. Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
US5663167A (en) 1992-12-09 1997-09-02 The United States Of America As Represented By The Department Of Health And Human Services Antipsychotic composition and method of treatment
IE930485A1 (en) 1993-06-28 1994-12-28 Hemisphere Ltd Antidepressant agents with a rapid onset of action
ZA948357B (en) 1994-06-16 1996-04-24 Lilly Co Eli Potentiation of drug response
HUP9903684A3 (en) 1995-12-22 2001-12-28 Lilly Co Eli Use of olanzapine for the preparation of pharmaceutical compositions treating depression
PL187926B1 (pl) 1996-03-25 2004-11-30 Lilly Co Eli Kompozycja farmaceutyczna do leczenia bólu
CA2250042A1 (en) 1996-03-25 1997-10-02 Eli Lilly And Company Treating pain using a synergistic combination of an atypical antipsychotic and a drug used in treatment of pain
US6159963A (en) 1996-03-29 2000-12-12 Eli Lilly And Company Method for treating substance abuse
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
ZA977967B (en) 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
ZA982368B (en) 1997-03-27 1998-09-23 Akzo Nobel Nv New therapeutic combinations
EP0919234A3 (de) 1997-10-17 1999-08-25 Eli Lilly And Company Potenzierung von Wirkstoffen durch Moxonidine
GB9801538D0 (en) 1998-01-23 1998-03-25 Merck Sharp & Dohme Pharmaceutical product
IL139008A0 (en) 1998-04-14 2001-11-25 Gen Hospital Corp Methods for treating neuropsychiatric disorders
GB2336534A (en) 1998-04-24 1999-10-27 Alec James Coppen Anti-depressant - Folic Acid Combination
US6500827B2 (en) 1998-05-08 2002-12-31 Pharmacia & Upjohn Company Drug combinations
HUP0101341A3 (en) 1998-05-08 2006-07-28 Upjohn Co New drug combinations
EP1077704A4 (de) 1998-05-21 2002-01-30 Lilly Co Eli Kombinationstherapie zur behandlung der depression
US6960577B2 (en) 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
JP2002516282A (ja) 1998-05-22 2002-06-04 イーライ・リリー・アンド・カンパニー 難治性鬱病の処置のための組合せ治療
US20030027817A1 (en) 1998-05-29 2003-02-06 Tollefson Gary Dennis Combination therapy for treatment of bipolar disorders
JP2002516864A (ja) 1998-05-29 2002-06-11 イーライ・リリー・アンド・カンパニー 両極性疾患の処置のための組合せ治療
US6420349B1 (en) 1998-08-24 2002-07-16 Bristol-Myers Squibb Company Isoxazolinone antibacterial agents
WO2000030649A1 (en) 1998-11-23 2000-06-02 Sepracor Inc. Pharmaceutical compositions containing olanzapine-n-oxide
CA2351718A1 (en) 1998-11-23 2000-06-02 Sepracor Inc. Desmethylolanzapine compositions and methods
US6174882B1 (en) 1998-11-23 2001-01-16 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
WO2000054764A2 (en) 1999-03-18 2000-09-21 Children's Hospital Research Foundation A method of treating bulimia nervosa and related eating disorders by administration of atypical antipsychotic medications
JP2002541098A (ja) 1999-04-06 2002-12-03 セプラコア インコーポレーテッド ジプラシドン代謝産物を用いる神経弛緩薬性障害および関連障害を治療するための方法および組成物
US6281207B1 (en) 1999-09-15 2001-08-28 Reed Richter Treatment of movement disorders by administration of mirtazapine
US6599532B2 (en) 2000-01-13 2003-07-29 Osmotica Corp. Osmotic device containing alprazolam and an antipsychotic agent
US6572890B2 (en) 2000-01-13 2003-06-03 Osmotica Corp. Osmotic device containing venlafaxine and an anti-psychotic agent
US6322503B1 (en) 2000-02-17 2001-11-27 G. Roger Sparhawk, Jr. Method of diagnosing, tracking, and treating depression
DE10018834A1 (de) 2000-04-15 2001-10-25 Lohmann Therapie Syst Lts Transdermale oder transmucosale Darreichungsformen mit einer nicotinhaltigen Wirkstoffkombination zur Raucherentwöhnung
AU2002232470B2 (en) 2001-01-02 2005-11-03 Pharmacia & Upjohn Company Llc New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
US20020123490A1 (en) 2001-03-01 2002-09-05 Pfizer Inc. Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis
EP1369129A4 (de) 2001-03-14 2005-08-03 Ono Pharmaceutical Co Heilmittel gegen depression mit einem ep1 antagonist als wirkstoff
BR0208922A (pt) 2001-04-19 2004-04-20 Warner Lambert Co Aminoácidos bicìclicos ou tricìclicos fundidos
WO2002087590A1 (en) 2001-04-26 2002-11-07 Ortho-Mcneil Pharmaceutical, Inc. Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics
DE10129320A1 (de) 2001-06-19 2003-04-10 Norbert Mueller Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
US6582737B2 (en) 2001-09-25 2003-06-24 Peirce Management, Llc Pharmaceutical composition containing two active ingredients for smoking cessation
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
WO2003066039A1 (en) 2002-02-08 2003-08-14 Abbott Laboratories Combination therapy for treatment of schizophrenia
EP1336406A1 (de) 2002-02-14 2003-08-20 Solvay Pharmaceuticals B.V. Partieller Dopamin-D2 Rezeptoragonist plus Substanzen mit Serotonin- und/oder Noradrenalin inhibitorischer Aktivität
WO2003101492A2 (en) 2002-05-30 2003-12-11 Neurosearch A/S Combination of atypical antipsychotic and serotonin reuptake inhibitor for the treatment of chronic pain
US20040127489A1 (en) 2002-07-29 2004-07-01 David Pickar Novel antipsychotic combination therapies and compositions useful therein
AU2003268026A1 (en) * 2002-07-30 2004-02-16 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
EP1556024A4 (de) 2002-10-25 2007-01-17 Collegium Pharmaceutical Inc Zusammensetzungen von milnacipran mitpulsativer freisetzung
US20040132826A1 (en) 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
CA2526562C (en) 2003-05-23 2011-06-28 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and mood stabilizers for treating mood disorders
EP1667686A1 (de) 2003-09-09 2006-06-14 Pfizer Products Inc. Kombination vom serotonin wiederaufnahme hemmern und norepinephrin wiederaufnahme hemmern
US20050250803A1 (en) 2003-11-26 2005-11-10 Pfizer Inc Combination of dopamine agonists and monoamine reuptake inhibitors
EP1713486A4 (de) 2003-12-02 2009-04-29 Sheldon Leslie James Kombinationstherapie für demenz, depression und apathie

Also Published As

Publication number Publication date
PE20040923A1 (es) 2005-01-22
CA2511619A1 (en) 2004-07-22
IL169358A0 (en) 2007-07-04
CN1989968A (zh) 2007-07-04
RU2005123808A (ru) 2006-02-20
NO20052359D0 (no) 2005-05-12
HK1101550A1 (en) 2007-10-18
CN1726039A (zh) 2006-01-25
RU2389490C2 (ru) 2010-05-20
ECSP055885A (es) 2005-11-22
WO2004060374A1 (en) 2004-07-22
US20170258788A1 (en) 2017-09-14
SI1575590T1 (sl) 2008-04-30
KR100842694B1 (ko) 2008-07-01
CN1989968B (zh) 2011-05-11
EP1723957A3 (de) 2013-01-23
KR20070093001A (ko) 2007-09-14
PT1575590E (pt) 2007-12-06
CY1108060T1 (el) 2014-02-12
IL169358A (en) 2013-04-30
ZA200503873B (en) 2006-08-30
CA2511619C (en) 2011-07-12
NO333291B1 (no) 2013-04-29
CN1726039B (zh) 2010-08-18
EP1575590B1 (de) 2007-10-24
MXPA05006857A (es) 2005-08-18
NZ540054A (en) 2007-09-28
DE60317098T2 (de) 2008-08-07
US20160310489A1 (en) 2016-10-27
ES2295677T3 (es) 2008-04-16
HK1145291A1 (en) 2011-04-15
AU2003295235B2 (en) 2008-06-19
US20190151308A1 (en) 2019-05-23
US20200289501A1 (en) 2020-09-17
EP1723957A2 (de) 2006-11-22
HK1082411A1 (en) 2006-06-09
BR0317771A (pt) 2005-11-22
JP4284524B2 (ja) 2009-06-24
NZ556779A (en) 2008-12-24
US9387182B2 (en) 2016-07-12
KR100858852B1 (ko) 2008-09-17
RU2356554C2 (ru) 2009-05-27
NO20052359L (no) 2005-07-18
ATE376419T1 (de) 2007-11-15
EP1575590A1 (de) 2005-09-21
US20140221388A1 (en) 2014-08-07
US9694009B2 (en) 2017-07-04
MY152919A (en) 2014-12-15
DK1575590T3 (da) 2008-02-11
RU2008131331A (ru) 2010-02-10
PL378214A1 (pl) 2006-03-20
JP2004217650A (ja) 2004-08-05
AU2003295235A1 (en) 2004-07-29
KR20050085906A (ko) 2005-08-29
PL211975B1 (pl) 2012-07-31

Similar Documents

Publication Publication Date Title
NO20052359D0 (no) Karbostyilderivater og serotonin reopptaks inhibitorer for behandling av humor forsyrrelser
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
ATE534391T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen
ATE370139T1 (de) Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs
ATE508114T1 (de) Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
DE50310516D1 (de) Fredericamycin-derivate
DE602005012481D1 (de) 2,7-substituierte 5-amino-4-hydroxy-8-(1h-indol-5-yl)-octanamid derivate als renin inhibitoren zur behandlung von bluthochdruck
ATE350377T1 (de) Substituierte 3-pyrrolidin-indol-derivate
UY28098A1 (es) Derivados de anilinopirazol útiles en el tratamiento de la diabetes
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
ATE410166T1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin- derivate zur behandlung von unfruchtbarkeit
ATE424823T1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin- derivate als arzneimittel zur behandlung von unfruchtbarkeit
ATE406895T1 (de) 4-phenyl-5-oxo-l,4,5,6,7,8-hexahydrochinolin- derivate als arzneimittel zur behandlung von unfruchtbarkeit
CY1116166T1 (el) Νεα μεθοδος για την αντιμετωπιση λοιμωξεων απο η.pylori
DE60311822D1 (de) Neue piperazinyl-pyrazinon-derivate zur behandlung von 5-ht2a rezeptor-bedingten erkrankungen
ATE267194T1 (de) Medikamente geeignet zur behandlung von proliferativen erkrankungen
ATE423772T1 (de) Morpholinderivate als inhibitoren der wiederaufnahme von norepinephrin
ATE407925T1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
ATE482217T1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
ATE402147T1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
DE60215947D1 (de) Pyridin-2-yl-methylamin-derivate zur behandlung von opiatsucht
DOP2003000766A (es) Derivados de anilinopirazol utiles en el tratamiento de la diabetes
TH77759A (de)

Legal Events

Date Code Title Description
8364 No opposition during term of opposition